Reuters logo
BRIEF-Heron Therapeutics gets FDA approval for Cinvanti
November 9, 2017 / 9:26 PM / 8 days ago

BRIEF-Heron Therapeutics gets FDA approval for Cinvanti

Nov 9 (Reuters) - Heron Therapeutics Inc

* Announces U.S. FDA approval of Cinvanti™ (aprepitant) injectable emulsion for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (cinv)

* U.S. Commercial launch of Cinvanti is planned for January 2018​

* Remain on-track with htx-011 which we expect to file for FDA review in 2018​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below